Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMLX NASDAQ:PRTC NASDAQ:PVLA NASDAQ:SRPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMLXAmylyx Pharmaceuticals$16.37+0.6%$15.09$5.31▼$18.60$1.81B-0.161.29 million shs1.85 million shsPRTCPureTech Health$17.42$17.51$14.50▼$19.92$424.04M1.1518,480 shsN/APVLAPalvella Therapeutics$118.68-0.1%$118.24$20.35▼$151.18$1.70B-0.15254,077 shs198,801 shsSRPTSarepta Therapeutics$17.26-2.2%$18.45$10.41▼$25.32$1.86B0.212.87 million shs2.37 million shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMLXAmylyx Pharmaceuticals+0.55%+8.77%+20.54%+18.37%+226.10%PRTCPureTech Health0.00%0.00%0.00%+10.71%-0.80%PVLAPalvella Therapeutics-0.13%+7.77%+4.11%-1.42%+426.53%SRPTSarepta Therapeutics-2.21%+9.38%+2.74%-27.39%-8.53%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMLXAmylyx Pharmaceuticals$16.37+0.6%$15.09$5.31▼$18.60$1.81B-0.161.29 million shs1.85 million shsPRTCPureTech Health$17.42$17.51$14.50▼$19.92$424.04M1.1518,480 shsN/APVLAPalvella Therapeutics$118.68-0.1%$118.24$20.35▼$151.18$1.70B-0.15254,077 shs198,801 shsSRPTSarepta Therapeutics$17.26-2.2%$18.45$10.41▼$25.32$1.86B0.212.87 million shs2.37 million shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMLXAmylyx Pharmaceuticals+0.55%+8.77%+20.54%+18.37%+226.10%PRTCPureTech Health0.00%0.00%0.00%+10.71%-0.80%PVLAPalvella Therapeutics-0.13%+7.77%+4.11%-1.42%+426.53%SRPTSarepta Therapeutics-2.21%+9.38%+2.74%-27.39%-8.53%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMLXAmylyx Pharmaceuticals 2.90Moderate Buy$23.0040.50% UpsidePRTCPureTech Health 1.00SellN/AN/APVLAPalvella Therapeutics 2.94Moderate Buy$199.5368.13% UpsideSRPTSarepta Therapeutics 2.08Hold$24.8143.74% UpsideCurrent Analyst Ratings BreakdownLatest PRTC, AMLX, PVLA, and SRPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026SRPTSarepta Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)6/8/2026AMLXAmylyx Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.005/26/2026SRPTSarepta Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)5/21/2026PVLAPalvella Therapeutics StephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$220.005/21/2026PVLAPalvella Therapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$240.005/18/2026PRTCPureTech Health Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/12/2026PVLAPalvella Therapeutics StephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$220.005/12/2026PVLAPalvella Therapeutics StephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$220.005/8/2026AMLXAmylyx Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/8/2026SRPTSarepta Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)4/28/2026AMLXAmylyx Pharmaceuticals MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$19.00 ➝ $21.00(Data available from 6/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMLXAmylyx Pharmaceuticals$87.37M20.83N/AN/A$2.78 per share5.89PRTCPureTech Health$4.66M91.01N/AN/A$12.65 per share1.38PVLAPalvella Therapeutics$42.81M39.75N/AN/A$2.36 per share50.29SRPTSarepta Therapeutics$2.20B0.83N/AN/A$10.89 per share1.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMLXAmylyx Pharmaceuticals-$144.74M-$1.50N/AN/AN/AN/A-55.69%-50.73%8/6/2026 (Estimated)PRTCPureTech Health-$109.74MN/AN/AN/AN/AN/AN/AN/A8/27/2026 (Estimated)PVLAPalvella Therapeutics-$41.72M-$4.17N/AN/AN/AN/A-56.87%-42.50%8/13/2026 (Estimated)SRPTSarepta Therapeutics-$713.41M-$0.96N/A6.640.19-2.94%7.56%2.94%8/5/2026 (Estimated)Latest PRTC, AMLX, PVLA, and SRPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026AMLXAmylyx Pharmaceuticals-$0.34-$0.37-$0.03-$0.37N/AN/A5/7/2026Q1 2026PVLAPalvella Therapeutics-$0.90-$1.20-$0.30-$1.20N/AN/A5/6/2026Q1 2026SRPTSarepta Therapeutics$0.9760$3.16+$2.1840$2.88$474.16 million$730.80 million4/10/2026H2 2025PRTCPureTech HealthN/A-$1.35N/A-$1.35N/A$1.40 million3/31/2026Q4 2025PVLAPalvella Therapeutics-$0.95-$1.08-$0.13-$1.08N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAMLXAmylyx PharmaceuticalsN/AN/AN/AN/AN/APRTCPureTech HealthN/AN/AN/AN/AN/APVLAPalvella TherapeuticsN/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMLXAmylyx PharmaceuticalsN/A17.8517.85PRTCPureTech HealthN/A6.596.59PVLAPalvella TherapeuticsN/A28.8828.88SRPTSarepta Therapeutics0.564.632.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMLXAmylyx Pharmaceuticals95.84%PRTCPureTech Health0.04%PVLAPalvella Therapeutics40.11%SRPTSarepta Therapeutics86.68%Insider OwnershipCompanyInsider OwnershipAMLXAmylyx Pharmaceuticals10.90%PRTCPureTech Health5.30%PVLAPalvella Therapeutics17.20%SRPTSarepta Therapeutics6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMLXAmylyx Pharmaceuticals200111.19 million99.07 millionOptionablePRTCPureTech Health10024.34 million23.05 millionNot OptionablePVLAPalvella TherapeuticsN/A14.34 million11.88 millionN/ASRPTSarepta Therapeutics1,372105.58 million98.29 millionOptionablePRTC, AMLX, PVLA, and SRPT HeadlinesRecent News About These CompaniesSarepta's Elevidys Showing Signs of Stabilization as siRNA Pipeline Gains Importance, RBC SaysJune 18, 2026 | finance.yahoo.comSarepta: Caution Still Warranted Despite FDA's Gene Therapy-Friendly StanceJune 18, 2026 | seekingalpha.comING Groep NV Cuts Stock Holdings in Sarepta Therapeutics, Inc. $SRPTJune 10, 2026 | marketbeat.comAll You Need to Know About Sarepta Therapeutics (SRPT) Rating Upgrade to BuyJune 8, 2026 | finance.yahoo.comIs Sarepta (SRPT) Using New Equity Plans To Quietly Redefine Its Post‑Profitability Playbook?June 8, 2026 | finance.yahoo.comSarepta Therapeutics, Inc. (SRPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8, 2026 | seekingalpha.comSRPT vs. ARGX: Which Stock Is the Better Value Option?June 8, 2026 | finance.yahoo.comAll You Need to Know About Sarepta Therapeutics (SRPT) Rating Upgrade to BuyJune 8, 2026 | zacks.comSRPT vs. ARGX: Which Stock Is the Better Value Option?June 8, 2026 | zacks.comBioGene Therapeutics Inc. Appoints Ty Howton to Board of DirectorsJune 8, 2026 | finance.yahoo.comSarepta Therapeutics, Inc. $SRPT Shares Sold by BNP Paribas Financial MarketsJune 7, 2026 | marketbeat.comImproving Profitability Supports Sarepta Therapeutics Inc. (SRPT) as One of the Most Shorted Small-Cap Stocks to BuyJune 5, 2026 | finance.yahoo.comImproving Profitability Supports Sarepta Therapeutics Inc. (SRPT) as One of the Most Shorted Small-Cap Stocks to BuyJune 5, 2026 | insidermonkey.comWhy Is Sarepta Therapeutics (SRPT) Down 19.9% Since Last Earnings Report?June 5, 2026 | finance.yahoo.comWhy Is Sarepta Therapeutics (SRPT) Down 19.9% Since Last Earnings Report?June 5, 2026 | zacks.comSarepta Shareholders Approve 2026 Equity and ESPP PlansJune 4, 2026 | tipranks.comSRPT Expands Into Huntington’s Disease With New First-in-Human TrialJune 4, 2026 | tipranks.comSarepta Therapeutics, Inc. (SRPT) Shareholder/Analyst Call TranscriptJune 4, 2026 | seekingalpha.comSarepta Therapeutics to Participate in Upcoming Investor ConferencesJune 1, 2026 | finance.yahoo.comSarepta Therapeutics to Participate in Upcoming Investor ConferencesJune 1, 2026 | businesswire.comIn Solid Cash Position, Sarepta Therapeutics Inc (SRPT) Outlines 2026 PrioritiesMay 27, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePRTC, AMLX, PVLA, and SRPT Company DescriptionsAmylyx Pharmaceuticals NASDAQ:AMLX$16.37 +0.09 (+0.55%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$16.52 +0.15 (+0.95%) As of 05:56 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.PureTech Health NASDAQ:PRTC$17.42 0.00 (0.00%) As of 06/22/2026PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.Palvella Therapeutics NASDAQ:PVLA$118.68 -0.16 (-0.13%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$118.68 +0.00 (+0.00%) As of 05:11 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.Sarepta Therapeutics NASDAQ:SRPT$17.26 -0.39 (-2.21%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$17.13 -0.13 (-0.75%) As of 06:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning These AI Stocks Have Insider Selling, But Buyers Still Have a Reason to Stay Apple’s Intel Deal Arrives at the Right Time for Its Stock Micron’s Sudden Plunge May Be an AI Buying Chance Amazon’s Pullback Deepens as a New FTC Risk Hits the Stock The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. How Does D-Wave's New Simulator Change the Quantum Computing Landscape? How Intel Is Packaging the Future of American Chips Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
